Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more
Genovate Biotechnology Co Ltd (4130) - Total Liabilities
Latest total liabilities as of December 2025: NT$126.05 Million TWD
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has total liabilities worth NT$126.05 Million TWD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genovate Biotechnology Co Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genovate Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crimson Wine
OTCQB:CWGL
|
USA | $32.01 Million |
|
Kintor Pharmaceutical Limited
PINK:KNTPF
|
USA | $175.89 Million |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
Korea | ₩11.60 Billion |
|
Eurobattery Minerals AB
F:5KD
|
Germany | €85.33 Million |
|
Aminex PLC
PINK:AEXFF
|
USA | $15.15 Million |
|
Unimot S.A
WAR:UNT
|
Poland | zł2.70 Billion |
|
Galaxy Far East
TWO:6227
|
Taiwan | NT$5.79 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Genovate Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genovate Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual total liabilities of Genovate Biotechnology Co Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$126.05 Million | -10.65% |
| 2024-12-31 | NT$141.08 Million | +7.13% |
| 2023-12-31 | NT$131.69 Million | -14.27% |
| 2022-12-31 | NT$153.60 Million | +12.41% |
| 2021-12-31 | NT$136.65 Million | -5.67% |
| 2020-12-31 | NT$144.87 Million | -12.03% |
| 2019-12-31 | NT$164.68 Million | -4.43% |
| 2018-12-31 | NT$172.32 Million | -61.02% |
| 2017-12-31 | NT$442.06 Million | +11.34% |
| 2016-12-31 | NT$397.04 Million | +1.04% |
| 2015-12-31 | NT$392.95 Million | -- |